HOTH News and Press, Hoth Therapeutics Inc. From 05/24/21

Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire NEW YORK , May 24, 2021 /PRNewswire/ -- Hoth Therapeutics , Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, ...

Hoth Therapeutics (HOTH) plans to host a virtual information session on its pipeline product, HT-005 Z-Pods on Tuesday, May 18th at 11:00am ET for interested shareholders.HT-005 Z-Pods is a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus ((CLE))....

Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus PR Newswire NEW YORK , May 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, ...

Hoth Therapeutics ([[HOTH]] +5.3%) has expanded its research agreement with Virginia Commonwealth University ((VCU)) for a potential COVID-19 treatment. Based on positive preclinical results, Hoth has amended its original scientific agreement with VCU and has agreed to fur...

Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic PR Newswire NEW YORK , May 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expa...

Hoth Therapeutics (HOTH) intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases in U.S.HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers, including:Aggressive systemic mastoc...

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers PR Newswire NEW YORK , May 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceu...

Hoth Therapeutics (HOTH) starts its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema. The trial is being conducted in Australia. For further details see: Hoth Therapeutics' human trial underway eval...

Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway PR Newswire NEW YORK , April 22, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused ...

Shares of Hoth Therapeutics Inc. (NASDAQ:HOTH) traded at a new 52-week low today of $1.51. This new low was reached on above average trading volume as 14.2 million shares traded hands, while the average 30-day volume is approximately 4.1 million shares. Hoth Therapeutics Inc is a develop...